News on companion diagnostics and drug/test co-development.
Myriad has partnered with Japanese firm SRL, a subsidiary of Miraca Group, to commercialize its BRACAnalysis Diagnostic System in Japan.
The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 15 skipping alterations.
The companies will work together to develop a next-generation sequencing-based companion diagnostic for an undisclosed cancer therapy.
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.
The company has overcome one major hurdle and is poised to clear another in the first half of this year, clearing the way for new test development.
